BIO-TECHNE Corp
TECHFigures shown here come from public SEC filings. Dates beside each section show the available history.
How BIO-TECHNE Corp Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Jun 30, 2025. The latest insider filing shown is dated Jun 4, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among BIO-TECHNE Corp's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-08-25 · Nusse Roeland: Larger than 9 of the 10 other insider sales of Common Stock on file. SEC filing
- 2025-08-25 · BAUMGARTNER ROBERT V: Larger than 9 of the 10 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-08 | Herr Amy E. · Director | Common Stock | S — Open market or private sale | −6,636 | 48.28 | SEC filing |
| 2026-02-17 | Herr Amy E. · Director | Common Stock | S — Open market or private sale | −1,976 | 59.11 | SEC filing |
| 2025-08-25 | BAUMGARTNER ROBERT V · Director | Common Stock | S — Open market or private sale | −17,040 | 56.21 | SEC filing |
| 2025-08-25 | Nusse Roeland · Director | Common Stock | S — Open market or private sale | −17,040 | 56.36 | SEC filing |
| 2025-06-09 | Herr Amy E. · Director | Common Stock | S — Open market or private sale | −1,280 | 49.77 | SEC filing |
| 2025-02-14 | Herr Amy E. · Director | Common Stock | S — Open market or private sale | −1,860 | 65.96 | SEC filing |
| 2025-01-27 | Kelderman Kim · Chief Executive Officer | Common Stock | S — Open market or private sale | −11,731 | 77.19 | SEC filing |
| 2025-01-27 | Kelderman Kim · Chief Executive Officer | Common Stock | S — Open market or private sale | −1,661 | 77.95 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-02 | Crouse Steven C. · President - Diag & Spatial Bi | Restricted Stock Units | M — Exercise or conversion of derivative security | −600 | SEC filing |
| 2026-06-02 | Crouse Steven C. · President - Diag & Spatial Bi | Common Stock | M — Exercise or conversion of derivative security | +600 | SEC filing |
| 2026-06-02 | Crouse Steven C. · President - Diag & Spatial Bi | Common Stock | F — Payment of exercise price or tax by delivering securities | −216 | SEC filing |
| 2026-05-08 | Herr Amy E. · Director | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −6,636 | SEC filing |
| 2026-05-08 | Herr Amy E. · Director | Common Stock | M — Exercise or conversion of derivative security | +6,636 | SEC filing |
| 2026-05-05 | Kelderman Kim · Chief Executive Officer | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −26,692 | SEC filing |
| 2026-05-05 | Bohnen Shane · SVP - General Counsel | Common Stock | M — Exercise or conversion of derivative security | +8,400 | SEC filing |
| 2026-05-05 | Bohnen Shane · SVP - General Counsel | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −8,400 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.